P/E ratio for Vertex Pharmaceuticals (VRTX)
P/E ratio as of January 2023 (TTM): 25.2
According to Vertex Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 25.1835. At the end of 2021 the company had a P/E ratio of 24.1.
P/E ratio history for Vertex Pharmaceuticals from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 24.1 | 6.4% |
| 2020 | 22.7 | -52.66% |
| 2019 | 47.9 | 138.24% |
| 2018 | 20.1 | -85.64% |
| 2017 | 140 | -189.35% |
| 2016 | -157 | 187.75% |
| 2015 | -54.5 | 43.97% |
| 2014 | -37.8 | 3.88% |
| 2013 | -36.4 | -57.41% |
| 2012 | -85.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 23.2 | -7.98% | 🇺🇸 USA |
 AbbVie ABBV | 19.4 | -22.92% | 🇺🇸 USA |
 Gilead Sciences GILD | 31.5 | 25.18% | 🇺🇸 USA |
 Merck MRK | 17.5 | -30.38% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 23.3 | -7.41% | 🇺🇸 USA |
 Enanta Pharmaceuticals
ENTA | -8.78 | -134.88% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.